Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings.

Silvio Fasullo, Francesco Giambanco, Salvatore Paterna, Stefania Cannizzaro, Sebastiano Scalzo, Sergio Cannizzaro, Francesco Giambanco, Pietro Di Pasquale, Sergio Fasullo, Giorgio Marenghini, Filippo Ganci, Giovanni Polizzi, Giuseppe Vitale

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group 1 (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), troponin I, creatine kinase and brain natriuretic peptide plasma levels], ECG and echocardiogram were performed at baseline and daily up to discharge. All of the patients were followed as outpatients for 3 months to evaluate any recurrence of pericarditis. The two groups were similar in age, sex and laboratory parameters [group 1 (the statin group), n=28 patients; gender, 18 male and ten female; and age, 29.5±5.7 years; group 2 (placebo group), n=27 patients; gender, 16 male/11 female; and age, 29.2±4.8 years]. The statin group, when compared with the placebo group, had a significantly faster reduction in CRP values (5.0±1.0 compared with 6.0±2.0 days respectively; P=0.022), ST segment normalization (3.5±1.0 compared with 4.5±1.0 days respectively; P=0.001), pericardial effusion (4.5±1.0 compared with 5.5±1.0 days respectively; P=0.001) and ESR (5.0±1 compared with 6.0±2 days respectively; P=0.022). Our results show that the combination of statin and indomethacin treatment in patients with acute pericarditis is feasible, with a significant reduction in inflammatory markers and a favourable trend in hospitalization time (5.5±2.0 compared with 6.5±2.0 days respectively; P=0.069). However, these preliminary findings require further studies in a larger sample of patients
Original languageEnglish
Pages (from-to)443-448
Number of pages6
JournalClinical Science
Volume113
Publication statusPublished - 2007

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pericarditis
Indomethacin
Placebos
Blood Sedimentation
C-Reactive Protein
Troponin I
Pericardial Effusion
Brain Natriuretic Peptide
Creatine Kinase
Electrocardiography
Hospitalization
Outpatients
Cell Count
Inflammation
Safety
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings. / Fasullo, Silvio; Giambanco, Francesco; Paterna, Salvatore; Cannizzaro, Stefania; Scalzo, Sebastiano; Cannizzaro, Sergio; Giambanco, Francesco; Di Pasquale, Pietro; Fasullo, Sergio; Marenghini, Giorgio; Ganci, Filippo; Polizzi, Giovanni; Vitale, Giuseppe.

In: Clinical Science, Vol. 113, 2007, p. 443-448.

Research output: Contribution to journalArticle

Fasullo, S, Giambanco, F, Paterna, S, Cannizzaro, S, Scalzo, S, Cannizzaro, S, Giambanco, F, Di Pasquale, P, Fasullo, S, Marenghini, G, Ganci, F, Polizzi, G & Vitale, G 2007, 'Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings.', Clinical Science, vol. 113, pp. 443-448.
Fasullo, Silvio ; Giambanco, Francesco ; Paterna, Salvatore ; Cannizzaro, Stefania ; Scalzo, Sebastiano ; Cannizzaro, Sergio ; Giambanco, Francesco ; Di Pasquale, Pietro ; Fasullo, Sergio ; Marenghini, Giorgio ; Ganci, Filippo ; Polizzi, Giovanni ; Vitale, Giuseppe. / Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings. In: Clinical Science. 2007 ; Vol. 113. pp. 443-448.
@article{fe37830402454aa0a06becce115c87e1,
title = "Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings.",
abstract = "The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group 1 (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), troponin I, creatine kinase and brain natriuretic peptide plasma levels], ECG and echocardiogram were performed at baseline and daily up to discharge. All of the patients were followed as outpatients for 3 months to evaluate any recurrence of pericarditis. The two groups were similar in age, sex and laboratory parameters [group 1 (the statin group), n=28 patients; gender, 18 male and ten female; and age, 29.5±5.7 years; group 2 (placebo group), n=27 patients; gender, 16 male/11 female; and age, 29.2±4.8 years]. The statin group, when compared with the placebo group, had a significantly faster reduction in CRP values (5.0±1.0 compared with 6.0±2.0 days respectively; P=0.022), ST segment normalization (3.5±1.0 compared with 4.5±1.0 days respectively; P=0.001), pericardial effusion (4.5±1.0 compared with 5.5±1.0 days respectively; P=0.001) and ESR (5.0±1 compared with 6.0±2 days respectively; P=0.022). Our results show that the combination of statin and indomethacin treatment in patients with acute pericarditis is feasible, with a significant reduction in inflammatory markers and a favourable trend in hospitalization time (5.5±2.0 compared with 6.5±2.0 days respectively; P=0.069). However, these preliminary findings require further studies in a larger sample of patients",
author = "Silvio Fasullo and Francesco Giambanco and Salvatore Paterna and Stefania Cannizzaro and Sebastiano Scalzo and Sergio Cannizzaro and Francesco Giambanco and {Di Pasquale}, Pietro and Sergio Fasullo and Giorgio Marenghini and Filippo Ganci and Giovanni Polizzi and Giuseppe Vitale",
year = "2007",
language = "English",
volume = "113",
pages = "443--448",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",

}

TY - JOUR

T1 - Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings.

AU - Fasullo, Silvio

AU - Giambanco, Francesco

AU - Paterna, Salvatore

AU - Cannizzaro, Stefania

AU - Scalzo, Sebastiano

AU - Cannizzaro, Sergio

AU - Giambanco, Francesco

AU - Di Pasquale, Pietro

AU - Fasullo, Sergio

AU - Marenghini, Giorgio

AU - Ganci, Filippo

AU - Polizzi, Giovanni

AU - Vitale, Giuseppe

PY - 2007

Y1 - 2007

N2 - The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group 1 (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), troponin I, creatine kinase and brain natriuretic peptide plasma levels], ECG and echocardiogram were performed at baseline and daily up to discharge. All of the patients were followed as outpatients for 3 months to evaluate any recurrence of pericarditis. The two groups were similar in age, sex and laboratory parameters [group 1 (the statin group), n=28 patients; gender, 18 male and ten female; and age, 29.5±5.7 years; group 2 (placebo group), n=27 patients; gender, 16 male/11 female; and age, 29.2±4.8 years]. The statin group, when compared with the placebo group, had a significantly faster reduction in CRP values (5.0±1.0 compared with 6.0±2.0 days respectively; P=0.022), ST segment normalization (3.5±1.0 compared with 4.5±1.0 days respectively; P=0.001), pericardial effusion (4.5±1.0 compared with 5.5±1.0 days respectively; P=0.001) and ESR (5.0±1 compared with 6.0±2 days respectively; P=0.022). Our results show that the combination of statin and indomethacin treatment in patients with acute pericarditis is feasible, with a significant reduction in inflammatory markers and a favourable trend in hospitalization time (5.5±2.0 compared with 6.5±2.0 days respectively; P=0.069). However, these preliminary findings require further studies in a larger sample of patients

AB - The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group 1 (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), troponin I, creatine kinase and brain natriuretic peptide plasma levels], ECG and echocardiogram were performed at baseline and daily up to discharge. All of the patients were followed as outpatients for 3 months to evaluate any recurrence of pericarditis. The two groups were similar in age, sex and laboratory parameters [group 1 (the statin group), n=28 patients; gender, 18 male and ten female; and age, 29.5±5.7 years; group 2 (placebo group), n=27 patients; gender, 16 male/11 female; and age, 29.2±4.8 years]. The statin group, when compared with the placebo group, had a significantly faster reduction in CRP values (5.0±1.0 compared with 6.0±2.0 days respectively; P=0.022), ST segment normalization (3.5±1.0 compared with 4.5±1.0 days respectively; P=0.001), pericardial effusion (4.5±1.0 compared with 5.5±1.0 days respectively; P=0.001) and ESR (5.0±1 compared with 6.0±2 days respectively; P=0.022). Our results show that the combination of statin and indomethacin treatment in patients with acute pericarditis is feasible, with a significant reduction in inflammatory markers and a favourable trend in hospitalization time (5.5±2.0 compared with 6.5±2.0 days respectively; P=0.069). However, these preliminary findings require further studies in a larger sample of patients

UR - http://hdl.handle.net/10447/23435

M3 - Article

VL - 113

SP - 443

EP - 448

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

ER -